MBI-006-COMUNITY: Combined AlloStim+Anti-PD-L1 in MSS Metastatic Colorectal Cancer

Condition: Colorectal Cancer

Sponsor: Mirror Biologics, Inc.

Full Title
Protocol MBI-006-COMUNITY: Phase II Open-Label Study to Assess the Safety and Efficacy of AlloStim® + Anti-PDL1 as Fourth Line Therapy for MSS Metastatic Colorectal Cancer

Study Treatment
AlloStim® +/- anti-PDL1 antibody avelumab
AlloStim®, is a patented, “off-the-shelf”, bioengineered, non-genetically altered, ex-vivo differentiated and expanded CD4+ Th1-like memory cell with anti-CD3/anti-CD28 coated microbeads attached (a/k/a Bioengineered Allograft Cells or “BAG” cells). AlloStim® cells produce type 1 cytokines such as interferon-gamma, GM-CSF and TNF-alpha and express high density CD40L. AlloStim® has potent immunomodulatory properties that are used to reverse engineer immune mechanisms and imprint them upon the immune systems of patients with cancer.

Eligibility/Info
Microsatellite stable/Mismatch repair proficient metastatic colorectal cancer that has come back or continued to grow after at least 2 lines of systemic therapy that included oxaliplatin, irinotecan, and TAS-102 or regorafenib.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Babylon Medical Oncology
Central Park Medical Oncology
Eastchester Cancer Center
Lake Success Medical Oncology
Patchogue Medical Oncology
Port Jefferson Medical Oncology
Port Jefferson Station Medical Oncology
Riverhead Medical Oncology

Go To Trial Homepage